share_log

Great West Life Assurance Co. Can Invests $470,000 in ITeos Therapeutics, Inc. (NASDAQ:ITOS)

Great West Life Assurance Co. Can Invests $470,000 in ITeos Therapeutics, Inc. (NASDAQ:ITOS)

大西部人壽保險公司可以將 47 萬美元投資於 ITEOS 治療股份有限公司（NASDAQ：ITOS）
Defense World ·  2023/02/04 05:02

Great West Life Assurance Co. Can bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the third quarter, according to its most recent filing with the SEC. The firm bought 24,710 shares of the company's stock, valued at approximately $470,000. Great West Life Assurance Co. Can owned about 0.07% of iTeos Therapeutics at the end of the most recent quarter.

大西部人壽保險公司根據其最近在美國證券交易委員會提交的文件，可以在第三季度購買了 ITEOS 治療有限公司（NASDAQ：ITOS-獲得評級）的新股份。該公司購買了該公司股票的 24,710 股，價值約為 47 萬美元。大西部人壽保險公司在最近一個季度結束時，可以擁有大約 0.07% 的 ITEOS 治療學。

Other hedge funds and other institutional investors have also bought and sold shares of the company. Prairiewood Capital LLC acquired a new position in iTeos Therapeutics in the 3rd quarter valued at $615,000. Alps Advisors Inc. acquired a new position in iTeos Therapeutics in the 2nd quarter valued at $434,000. Rafferty Asset Management LLC grew its stake in iTeos Therapeutics by 2.1% in the 2nd quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock valued at $2,047,000 after buying an additional 2,067 shares during the last quarter. Principal Financial Group Inc. grew its stake in iTeos Therapeutics by 22.7% in the 2nd quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock valued at $3,455,000 after buying an additional 31,004 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 39.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock valued at $119,000 after buying an additional 1,629 shares during the last quarter.

其他對沖基金和其他機構投資者也買賣了該公司的股票。草木資本有限責任公司在第三季度收購了 ITEOS 治療學的新職位，價值為 615,000 美元。阿爾卑斯顧問公司在第二季度收購了 ITEOS 治療學的新職位，價值為 434,000 美元。萊佛蒂資產管理有限責任公司在第二季度將其在 ITEOS 治療的股份增長了 2.1％。萊佛蒂資產管理有限責任公司在上一季度額外購買 2,067 股股票後，擁有該公司股票的 99,368 股價值為 2,047,000 美元。信安金融集團股份有限公司在第二季度增長了 22.7％ 的 ITEO 治療學的股份。信安金融集團股份有限公司在上一季度額外購買 31,004 股股份後，現擁有該公司 167,750 股股份，價值為 3,455,000 美元。最後，維圖斯 ETF 顧問有限責任公司在第二季度將其在 ITEO 治療學的股份增加了 39.1％。維圖斯 ETF 顧問有限責任公司在上一季度額外購買 1,629 股股票後，擁有該公司 5,790 股價值為 119,000 美元的股票。

Get
取得
iTeos Therapeutics
ITEOS 治療學
alerts:
警報：

iTeos Therapeutics Trading Up 2.3 %

ITEOS 治療學交易增長了 2.3%

NASDAQ:ITOS opened at $20.77 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $16.21 and a 1 year high of $37.88. The firm's fifty day simple moving average is $19.88 and its 200 day simple moving average is $20.92. The firm has a market capitalization of $739.00 million, a PE ratio of 3.02 and a beta of 1.37.

納斯達克：ITOS 上週五以 20.77 美元開盤，ITEOS 治療股份有限公司擁有 1 年低點 16.21 美元和 1 年最高的 37.88 美元。該公司的五十天簡單移動平均線為 19.88 美元，其 200 日簡單移動平均線為 20.92 美元。該公司的市值為 739.00 萬美元，私募股權比率為 3.02，測試版為 1.37。

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $19.49 million during the quarter, compared to analyst estimates of $42.05 million. iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post 2.85 EPS for the current fiscal year.
ITEOS 治療學（NASDAQ：ITOS-獲取評分）上次發布了其季度收益業績，週四，11 月 10 日。該公司報告了本季度的每股盈利 0.03 美元，缺少 0.07 美元（0.04 美元）的一致估計值。該公司在本季度的收入為 19.49 萬美元，而分析師估計為 4.05 億美元，iToS 治療的股權回報率為 42.62％，淨利潤率為 57.48%。作為一個小組，分析師預計，iToS 治療, Inc. 將在本財政年度發布 2.85 每股盈利。

iTeos Therapeutics Company Profile

ITEOS 治療公司簡介

(Get Rating)

(取得評分)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Itemos Therapetics, Inc 是一家臨床階段生物製藥公司，致力於為患者提供免疫腫瘤治療的發現和開發。公司的產品線包括二期臨床試驗中腺苷 A2AR 拮抗劑的小分子拮抗劑，以及 EOS-448（一種 TIGIT 或 T 細胞免疫受體的拮抗劑），具有 Ig 和 ITIM 域的拮抗劑（在 1/2 期臨床試驗中），以及用於接合 Fc γ 受體或 Fc。R 激活樹突狀細胞和巨噬細胞，促進抗體依賴性細胞毒性或 ADCC 活性。

See Also

另請參閱

  • Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
  • Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
  • Zimmer Biomet Beats on Earnings, Growth May be Priced In
  • AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
  • Ford Stock Going Forward After Big Earnings Flop
  • Insiders And Institutions Buy Wolverine Worldwide
  • 獲取有關 ITEOS 治療學研究報告的免費副本
  • 竹篙股票值得嗎？您應該投資竹篙股嗎？
  • 齊默生物特在盈利上擊敗，增長可能會定價
  • 人工智能軟件製造商 EPAM 擁有最大的技術行業集會
  • 大盈利翻牌後福特股票前進
  • 業內人士和機構購買金剛狼全球

Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating).

想看看還有哪些對沖基金持有 ITOS？ 訪問 Holdingschannel.com 以獲取有關 ITEOS 治療有限公司（NASDAQ：ITOS-獲得評分）的最新 13 樓文件和內部交易。

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收有關 ITEOS 治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 ITEOS 治療和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論